Warfarin, a Comprehensive Review by Jay Patel – Presentation.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Warfarin, a Comprehensive Review by Jay Patel – Presentation.Pdf Warfarin: A Comprehensive Review Jay M Patel, PharmD Objectives • Explain the important pharmacodynamic and pharmacokinetic properties of warfarin • Describe the role of warfarin in the inpatient setting • Identify factors that may contribute to variability in the INR with warfarin use • Discuss warfarin initiation and dose adjustments based on a comprehensive review of the patient Disclaimer Dr. Patel has no actual or potential conflict of interest associated with this presentation Coumadin® (Warfarin) • Clinical Pharmacology – Inhibit synthesis of Vitamin K dependent clotting factors • II, VII, IX and X • Protein C and S • Mechanism of Action – “Vitamin K antagonist” (VKA) – Inhibit C1 subunit of vitamin K epoxide reductase (VKORC1) enzyme complex Coumadin® (Warfarin) • Elimination half-lives of vitamin K- dependent proteins Factor Half-Life II 42-72 hours VII 4-6 hours IX 21-30 hours X 27-48 hours Protein C 8 hours Protein S 60 hours Clotting Cascade.http://medlibes.com/uploads/Screen%20shot%202010-07-30%20at%2012.56.57%20PM.png. Accessed May 15, 2015. Warfarin Response. El Camino Hospital. http://elcaminogmi.dnadirect.com/img/content/tests/drug_response/howWarfarinAffectsBloodClotting.gif. Date Accessed May 14, 2015. Accessed May 14, 2015 Question 1 • Warfarin, through the inhibition of VKOR, inhibits the production of which factors? A. II, VIII, XII, Protein C and Protein S B. I, II, III, and X C. XI, Protein C and Protein S D. II, VII, IX, X, Protein C and Protein S Pharmacokinetics • Racemic mixture of R- and S- enantiomers – S- 2 to 5 times more anticoagulant activity • Completely absorbed after oral administration • Small volume of distribution – ~0.14 L/Kg Pharmacokinetics • Approximately 99% protein bound • Extensive hepatic metabolization – CYP2C9, 2C19, 2C8, 2C18, 1A2 and 3A4 • S- enantiomer 2C9 • R- enantiomer 1A2/3A4 – Minimally active metabolites excreted mainly in urine and lesser extent in bile • Singe dose terminal half-life ~ 1 week • Effective half life 20-60 hours Question 2 • Which entantiomer is a more potent anticoagulant and is primarily metabolized by CYP2C9? A. R-enantiomer B. S-enantiomer Warfarin Initiation – CHADS2 Lamichhane, D. Update on secondary prevention of ischaemic stroke. http://jpma.org.pk/images/July2014/Update%20on%20secondary%20table2.jpg Published July, 2014. Accessed May 14, 2015. FDA Approved Indications • Prophylaxis and/or treatment of – Venous thrombosis and its extension, and pulmonary embolism – Thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement • Reduce risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolism after MI Other Uses of Warfarin • Orthopedic, general or urological surgery – Hip or knee arthroplasty – Hip fracture surgery – Abdominal or pelvic surgery – Prevention of transient ischemic attacks Warfarin Dosing Inpatient • Initiation overlap for heparin/low molecular weight heparin (LMWH) and VKA – Historically • Unfractionated heparin (UFH) 5-7 days then co- administer VKA – Contemporary practice • VKA therapy initiated day 1 or 2 UFH/LMWH Warfarin Dosing Inpatient • Initial dose selection – Doses should be individualized based on a comprehensive review of the patient – General recommendations • 5 mg daily for healthy individuals • 2.5mg daily for individuals with concomitant factors Patient Factors • Increased age • Diarrhea • Varying size • Thyroid disorders • Nutritional status • Hepatic/renal • Drug-drug dysfunction interactions • Genomic variants* • Chronic heart failure – CYP2C9 (*2 or *3 alleles) • Elevated baseline – VKORC1 INR polymorphism *The American College of Chest Physicians recommends against the use of routine pharmacogenomic testing to guide dosing Question 3 • Which of the following patient factors can influence initial warfarin dosing and INR variability? A. Age B. Diarrhea C. Nutritional status D. Chronic heart failure exacerbation E. All of the above Target INR • International normalized ratio (INR) – (Patient PT/Mean normal PT)ISI – ISI = International Sensitivity Index • Responsiveness of given thromboplastin to reduction of the vitamin K-dependent coagulation factors • More responsive agent low ISI Recommended Target INR Indication INR Duration Antiphospholipid Syndrome No additional risk factors 2 to 3 Indefinite Recurrent events with therapeutic INRs 2.5 to 3.5 Indefinite DVT and PE Transient/reversible risk factor 2 to 3 3 Months Unprovoked 2 to 3 3 Months Second episode unprovoked 2 to 3 Long-term With active cancer or LMWH for 3-6 months 2 to 3 Indefinite Atrial Fibrillation With prior CVA or TIA or systemic embolism 2 to 3 Long-term With mitral stenosis 2 to 3 Long-term Following open heart surgery 2 to 3 4 weeks PPX = prophylaxis; VT = venous thrombosis Recommended Target INR Indication INR Duration Mechanical Heart Valve Aortic bileaflet or tilting disk 2 to 3 Long-term Mitral bileaflet or tilting disk 2.5 to 3.5 Long-term Aortic or mitral caged ball or caged disk 2.5 to 3.5 Long-term Any valve with additional risk factor 2.5 to 3.5 Long-term Bioprosthetic Heart Valve Aortic N/A Aspirin 50-100mg Mitral 2 to 3 3 months W/ prior history of systemic embolism 2 to 3 3 months W/ left atrial thrombus 2 to 3 Until resolves Cardioembolic Ischemic Stroke 2 to 3 Long-term Factors Influencing INR Variability • Other medications – Antibiotics – CYP450 inducers/inhibitors • Diet • Increased/decreased activity • Increased/decreased weight Factors Influencing INR Variability • Antibiotics – Disrupt vitamin K-producing intestinal flora • Increased effect of warfarin • Inhibit metabolism of warfarin – Generally within one week Factors Influencing INR Variability • CYP450 Inducers • CYP450 Inhibitors – Rifampin – Antifungals – Phenobarbital – Macrolides – Phenytoin – Fluoroquinolones – Prednisone – Antiretrovirals – St. John’s Wort – Amiodarone – Ritonavir – Propafenone – Smoking – Isoniazid – Fluvastatin – Grapefruit Factors Influencing INR Variability • Other medications – Amiodarone – Ascorbic acid – Acetaminophen – Corticosteroids – Sucralfate – Statins Factors Influencing INR Variability • Foods high in vitamin K – Leafy, green vegetables • Kale • Spinach • Brussel sprouts • Asparagus • Basil • Malnutrition • Diet ordered in house – NPO Dose Adjustments Target INR Goal of 2 -3 Warfarin Increased Warfarin Day INR Value Sensitivity Starting Dose (mg) Starting Dose Day 1 5 mg < 1.5 2.5 mg 5 mg < 1.5 2.5 mg 2.5mg 1.5 – 1.9 1 – 1.5 mg Day 2 1 – 2.5 mg 2 – 2.5 0.5 – 1 mg 0 mg > 2.5 0 mg 5 – 10 mg < 1.5 2.5 – 5 mg 2.5 – 5 mg 1.5 – 1.9 1 – 2.5 mg Day 3 0 – 2.5 mg 2 – 3 0 – 1 mg 0 mg > 3 0 mg Dose Adjustments Warfarin Increased Warfarin Starting Dose INR Value Sensitivity Starting Dose 10 mg < 1.5 5 mg 5 – 7.5 mg 1.5 – 1.9 3 – 5 mg Day 4 0 – 5 mg 2 - 3 0 – 2.5 mg 0 mg > 3 0 mg 10 mg < 1.5 5 mg 7.5 – 10 mg 1.5 – 1.9 3 – 5 mg Day 5 0 – 5 mg 2 - 3 0 – 2.5 mg 0 mg > 3 0 mg 7.5 – 12.5 mg < 1.5 3 – 7.5 mg 5 – 10 mg 1.5 – 1.9 2.5 – 5 mg Day 6 0 – 7.5 mg 2 – 3 0 – 4 mg 0 mg > 3 0 mg Increased Bleeding Risk • Current antiplatelet • End stage renal therapy disease • Elevated PT • GI bleed w/in past 30 – Normal: 9.4 – 12.5 days seconds • Surgery w/in past 2 • Thrombocytopenia weeks – Platelet <75 K/uL • Intracranial bleed w/in • Significant hepatic past 30 days disease • Medications – Cirrhosis or total bilirubin >2.4 mg/dL • Alcohol abuse history Signs and Symptoms of Bleeding • Low hemoglobin/hematocrit • Blood in urine, stool, or sputum • Intracranial bleeding – Confusion – Weakness – Loss of vision • Lightheadedness • Weakness • Black, tarry stools • Bleeding gums • Severe abdominal pains Warfarin Reversal FFP = fresh frozen plasma, PCC = prothrombin complex concentrate Warfarin Reversal • Kcentra® (prothrombin complex concentrate) – Factors II, VII, IX, and X – Proteins C and S • Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K Antagonist therapy in adults with: – Acute major bleeding – Need for an urgent surgery/invasive procedure Warfarin Reversal • Kcentra® Dosing – Administer with Vitamin K concurrently Pre-treatment INR 2 – <4 4 – 6 >6 Dose* of Kcentra (Units of Factor IX) 25 35 50 / kg body weight Maximum dose Not to exceed Not to exceed Not to exceed (units of Factor IX) 2500 3500 5000 * Dose based on actual potency as stated on the carton Pharmacy Resources • American College of Chest Physicians (CHEST Journal) • Pharmacy.uchc.edu – Inpatient collaborative practice protocol • Warfarindosing.org • Global RPh Conclusion Initial dose selection • Target INR • New start versus continuing maintenance • Drug, disease, dietary interactions • Laboratory findings – Hepatic/renal function – Nutritional status – PT/INR – Hemoglobin/hematocrit Case 1 • A 75 year old female patient is being bridged to warfarin therapy following a pulmonary embolism. She has a past medical history of hypothyroidism, type 2 diabetes, and hypertension. • Her baseline INR is 1.4. • Her renal and hepatic function are normal. Case 1 • Home Medication list – Lisinopril 5 mg QD – Levothyroxine 50 mcg QD – Metformin 500mg BID • Inpatient Medication List – Lisinopril 2.5mg QD – Insulin sliding scale Case 1 • What initial dose of warfarin would you recommend for this patient? A. 1 mg B. 2.5 mg C. 5 mg D. 7.5 mg E. 10 mg Case 1 • The medical team disagrees with your recommendation and gives the patient a 5 mg dose for 2 days. The INR is found to be 7.9 after the patient received the warfarin 5 mg. The patient has no evidence and is not expressing any symptoms of bleeding. Case 1 • The medical resident contacts you and asks what the next step should be regarding this patient’s therapy. What would you suggest? A. Administer 5 mg vitamin K PO B. Administer 5 mg vitamin K IV C. Hold warfarin until INR is therapeutic References • Ageno, et al. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Recommended publications
  • Guideline on Clinical Investigation of Recombinant and Human Plasma-Derived 9 Factor IX Products’ (EMA/CHMP/BPWP/144552/2009 Rev
    1 15 November 2018 2 EMA/CHMP/BPWP/144552/2009 rev. 2 Corr. 1 3 Committee for medicinal products for human use (CHMP) 4 Guideline on clinical investigation of recombinant and 5 human plasma-derived factor IX products 6 Draft Draft Agreed by Blood Products Working Party (BPWP) August 2018 Adopted by Committee for Medicinal Products for Human Use (CHMP) 15 November 2018 Start of public consultation 3 December 2018 End of public consultation 30 June 2019 7 8 This guideline replaces ‘Guideline on clinical investigation of recombinant and human plasma-derived 9 factor IX products’ (EMA/CHMP/BPWP/144552/2009 Rev. 1, Corr. 1) 10 Comments should be provided using this template. The completed comments form should be sent to [email protected] 11 Keywords Recombinant factor IX, plasma-derived factor IX, efficacy, safety, immunogenicity, inhibitor, thrombogenicity, anaphylactic reactions, potency assays 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 12 Guideline on the clinical investigation of recombinant and 13 human plasma-derived factor IX products 14 Table of contents 15 Executive summary ..................................................................................... 4 16 1. Introduction (background) .....................................................................
    [Show full text]
  • Enoxaparin Sodium Solution for Injection, Manufacturer's Standard
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLOVENOX® Enoxaparin sodium solution for injection 30 mg in 0.3 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 40 mg in 0.4 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 60 mg in 0.6 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 80 mg in 0.8 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 100 mg in 1 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 300 mg in 3 mL solution (100 mg/mL), multidose vials for subcutaneous or intravenous injection PrLOVENOX® HP Enoxaparin sodium (High Potency) solution for injection 120 mg in 0.8 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 150 mg in 1 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection Manufacturer’s standard Anticoagulant/Antithrombotic Agent ATC Code: B01AB05 Product Monograph – LOVENOX (enoxaparin) Page 1 of 113 sanofi-aventis Canada Inc. Date of Initial Approval: 2905 Place Louis-R.-Renaud February 9, 1993 Laval, Quebec H7V 0A3 Date of Revision September 7, 2021 Submission Control Number: 252514 s-a version 15.0 dated September 7, 2021 Product Monograph – LOVENOX (enoxaparin) Page 2 of 113 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................
    [Show full text]
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
    [Show full text]
  • Identification of an Alpha-1 Antitrypsin Variant with Enhanced Specificity For
    www.nature.com/scientificreports OPEN Identifcation of an alpha‑1 antitrypsin variant with enhanced specifcity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis Varsha Bhakta1, Mostafa Hamada2, Amy Nouanesengsy2, Jessica Lapierre2, Darian L. Perruzza2 & William P. Shefeld1,2* Coagulation Factor XIa (FXIa) is an emerging target for antithrombotic agent development. The M358R variant of the serpin alpha‑1 antitrypsin (AAT) inhibits both FXIa and other proteases. Our aim was to enhance the specifcity of AAT M358R for FXIa. We randomized two AAT M358R phage display libraries at reactive centre loop positions P13‑P8 and P7‑P3 and biopanned them with FXIa. A bacterial expression library randomized at P2′‑P3′ was also probed. Resulting novel variants were expressed as recombinant proteins in E. coli and their kinetics of FXIa inhibition determined. The most potent FXIa‑inhibitory motifs were: P13‑P8, HASTGQ; P7‑P3, CLEVE; and P2‑P3′, PRSTE (respectively, novel residues bolded). Selectivity for FXIa over thrombin was increased up to 34‑fold versus AAT M358R for these single motif variants. Combining CLEVE and PRSTE motifs in AAT‑RC increased FXIa selectivity for thrombin, factors XIIa, Xa, activated protein C, and kallikrein by 279‑, 143‑, 63‑, 58‑, and 36‑fold, respectively, versus AAT M358R. AAT‑RC lengthened human plasma clotting times less than AAT M358R. AAT‑RC rapidly and selectively inhibits FXIa and is worthy of testing in vivo. AAT specifcity can be focused on one target protease by selection in phage and bacterial systems coupled with combinatorial mutagenesis. Trombosis, the blockage of intact blood vessels by occlusive clots, continues to impose a heavy clinical burden, and is responsible for one quarter of deaths world-wide1.
    [Show full text]
  • Rivaroxaban Versus Warfarin for Treatment and Prevention Of
    Costa et al. Thrombosis Journal (2020) 18:6 https://doi.org/10.1186/s12959-020-00219-w RESEARCH Open Access Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis Olivia S. Costa1,2, Stanley Thompson3, Veronica Ashton4, Michael Palladino5, Thomas J. Bunz6 and Craig I. Coleman1,2* Abstract Background: African Americans are under-represented in trials evaluating oral anticoagulants for the treatment of acute venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban versus warfarin for the treatment of VTE in African Americans. Methods: We utilized Optum® De-Identified Electronic Health Record data from 11/1/2012–9/30/2018. We included African Americans experiencing an acute VTE during a hospital or emergency department visit, who received rivaroxaban or warfarin as their first oral anticoagulant within 7-days of the acute VTE event and had ≥1 provider visit in the prior 12-months. Differences in baseline characteristics between cohorts were adjusted using inverse probability-of-treatment weighting based on propensity scores (standard differences < 0.10 were achieved for all covariates). Our primary endpoint was the composite of recurrent VTE or major bleeding at 6-months. Three- and 12-month timepoints were also assessed. Secondary endpoints included recurrent VTE and major bleeding as individual endpoints. Cohort risk was compared using Cox regression and reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Results: We identified 2097 rivaroxaban and 2842 warfarin users with incident VTE. At 6-months, no significant differences in the composite endpoint (HR = 0.96, 95%CI = 0.75–1.24), recurrent VTE (HR = 1.02, 95%CI = 0.76–1.36) or major bleeding alone (HR = 0.93, 95%CI = 0.59–1.47) were observed between cohorts.
    [Show full text]
  • In Search of a Protein Nucleator of Hydroxyapatite in Bone
    IN SEARCH OF A PROTEIN NUCLEATOR OF HYDROXYAPATITE IN BONE Carmel O Domeni cucci A rhesis subrnitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Biochemistq University of Toronto O Copyright by Canne10 Domenicucci 1997 National Library Bibiiothéque nationale B*m of Canada du Canada Acquisitions and Acquisitions et Bibliographic Services sewices bibliographiques 395 Wellington Street 395. rue Wellington OttawaON K1AON4 OrtawaON KIAON4 Canada Canada Your iVe Vaire rehrefue Our !W Notre referwice The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or seil reproduire, prêter, distribuer ou copies of ths thesis in rnicroform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/fh, de reproduction sur papier ou sur format électronique. The author retallis ownership of the L'auteur conserve la propriété du copyright in ths thesis. Neither the droit d'auteur qui protège cette thése. thesis nor substantial extracts &om it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. Yn Search of a Protein Nucleator of Hydroxyapatite in Bone" Doctor of Philosophy. 1997 Carme10 Domenicucci Department of Biochemistry University of Toronto The formation of mineralized conneciive tissues is characterized by the nucleation of hydroxyapatite crystals that are generated initiaily within the gap region of collagen fibrils. However, the mechanisrn of mineral nuckation has not been resolved.
    [Show full text]
  • Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-Target Organisms Katherine Horak U.S
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln USDA National Wildlife Research Center - Staff U.S. Department of Agriculture: Animal and Plant Publications Health Inspection Service 2018 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine Horak U.S. Department of Agriculture, [email protected] Penny M. Fisher Landcare Research Brian M. Hopkins Landcare Research Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc Part of the Life Sciences Commons Horak, Katherine; Fisher, Penny M.; and Hopkins, Brian M., "Pharmacokinetics of Anticoagulant Rodenticides in Target and Non- target Organisms" (2018). USDA National Wildlife Research Center - Staff Publications. 2091. https://digitalcommons.unl.edu/icwdm_usdanwrc/2091 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff ubP lications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Chapter 4 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine E. Horak, Penny M. Fisher, and Brian Hopkins 1 Introduction The concentration of a compound at the site of action is a determinant of its toxicity. This principle is affected by a variety of factors including the chemical properties of the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route of exposure, and physiological properties of the organism. Many compounds have to undergo chemical changes, biotransformation, into more toxic or less toxic forms. Because of all of these variables, predicting toxic effects and performing risk assess- ments of compounds based solely on dose are less accurate than those that include data on absorption, distribution, metabolism (biotransformation), and excretion of the compound.
    [Show full text]
  • Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: a Comparative in Situ Hybridization Analysis
    The Journal of Neuroscience, March 1993. 73(3): 1258-1279 Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: A Comparative in situ Hybridization Analysis Martin K.-H. Schafer,i-a Robert Day,* William E. Cullinan,’ Michel Chri?tien,3 Nabil G. Seidah,* and Stanley J. Watson’ ‘Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan 48109-0720 and J. A. DeSeve Laboratory of *Biochemical and 3Molecular Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada H2W lR7 Posttranslational processing of proproteins and prohor- The participation of neuropeptides in the modulation of a va- mones is an essential step in the formation of bioactive riety of CNS functions is well established. Many neuropeptides peptides, which is of particular importance in the nervous are synthesized as inactive precursor proteins, which undergo system. Following a long search for the enzymes responsible an enzymatic cascade of posttranslational processing and mod- for protein precursor cleavage, a family of Kexin/subtilisin- ification events during their intracellular transport before the like convertases known as PCl, PC2, and furin have recently final bioactive products are secreted and act at either pre- or been characterized in mammalian species. Their presence postsynaptic receptors. Initial endoproteolytic cleavage occurs in endocrine and neuroendocrine tissues has been dem- C-terminal to pairs of basic amino acids such as lysine-arginine onstrated. This study examines the mRNA distribution of (Docherty and Steiner, 1982) and is followed by the removal these convertases in the rat CNS and compares their ex- of the basic residues by exopeptidases. Further modifications pression with the previously characterized processing en- can occur in the form of N-terminal acetylation or C-terminal zymes carboxypeptidase E (CPE) and peptidylglycine a-am- amidation, which is essential for the bioactivity of many neu- idating monooxygenase (PAM) using in situ hybridization ropeptides.
    [Show full text]
  • VIEW Open Access Vitamin K Antagonist Use: Evidence of the Difficulty of Achieving and Maintaining Target INR Range and Subsequent Consequences Jeff R
    Schein et al. Thrombosis Journal (2016) 14:14 DOI 10.1186/s12959-016-0088-y REVIEW Open Access Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences Jeff R. Schein1, C. Michael White2,3, Winnie W. Nelson1, Jeffrey Kluger3, Elizabeth S. Mearns2 and Craig I. Coleman2,3* Abstract Vitamin K antagonists (VKAs) are effective oral anticoagulants that are titrated to a narrow therapeutic international normalized ratio (INR) range. We reviewed published literature assessing the impact of INR stability - getting into and staying in target INR range - on outcomes including thrombotic events, major bleeding, and treatment costs, as well as key factors that impact INR stability. A time in therapeutic range (TTR) of ≥65 % is commonly accepted as the definition of INR stability. In the real-world setting, this is seldom achieved with standard-of-care management, thus increasing the patients’ risks of thrombotic or major bleeding events. There are many factors associated with poor INR control. Being treated in community settings, newly initiated on a VKA, younger in age, or nonadherent to therapy, as well as having polymorphisms of CYP2C9 or VKORC1, or multiple physical or mental co-morbid disease states have been associated with lower TTR. Clinical prediction tools are available, though they can only explain <10 % of the variance behind poor INR control. Clinicians caring for patients who require anticoagulation are encouraged to intensify diligence in INR management when using VKAs and to consider appropriate use of newer anticoagulants as a therapeutic option. Keywords: Vitamin K antagonists, International normalized ratio, Anticoagulation, Atrial fibrillation, Venous thromboembolism Background (within 72–96 h after dosing) and an anticoagulated Vitamin K antagonists (VKAs) such as warfarin inhibit state.
    [Show full text]
  • Gene Therapy Expression Vectors Based on the Clotting Factor IX Promoter
    Gene Therapy (1999) 6, 1584–1589 1999 Stockton Press All rights reserved 0969-7128/99 $15.00 http://www.stockton-press.co.uk/gt Gene therapy expression vectors based on the clotting Factor IX promoter H Hoag, J Gore, D Barry and CR Mueller Department of Biochemistry and Cancer Research Laboratories, Queen’s University, Kingston, Ontario, Canada The liver is one of the prime targets for gene therapy, and moter. Introduction of this element increases promoter the correction of defects in a variety of clotting factor genes activity at least 20-fold over the proximal promoter alone is one of the main goals of liver-directed therapies. The use when assayed in the human liver cell line Hep G2. This of transcriptional regulatory elements derived from these optimized promoter is significantly more active than the genes may provide for the optimal expression of trans- SV40 enhancer/early promoter. The expression of the opti- duced genes. We have applied our knowledge of the pro- mized Factor IX promoter is also more persistent in the moter structure of the clotting Factor IX gene to design short term. The inclusion of a liver-specific locus control optimized expression vectors for use in gene therapy. The region, derived from the apolipoprotein E/C locus, did not activity of the proximal promoter has been augmented by further augment expression levels. These Factor IX vectors the introduction of a multimerized upstream site which we also exhibit a high degree of tissue specificity, as meas- have previously shown to be a prime regulator of the pro- ured by transfection into breast and muscle cell lines.
    [Show full text]
  • The Two Faces of Thrombosis: Coagulation Cascade and Platelet Aggregation. Are Platelets the Main Therapeutic Target
    Thrombosis and Circulation Open Access Cimmino et al., J Thrombo Cir 2017, 3:1 Review Article Open Access The Two Faces of Thrombosis: Coagulation Cascade and Platelet Aggregation. Are Platelets the Main Therapeutic Target? Giovanni Cimmino*, Salvatore Fischetti and Paolo Golino Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, Naples, Italy *Corresponding author: Giovanni Cimmino, MD, PhD, Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, via Leonardo Bianchi, 180131 Naples, Italy. Tel: +39-081-7064175, Fax: +39-081-7064234; E-mail: [email protected] Received date: Dec 28, 2016, Accepted date: Jan 27, 2017, Published date: Jan 31, 2017 Copyright: © 2017 Giovanni C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Acute thrombus formation is the pathophysiological substrate underlying several clinical conditions, such as acute coronary syndrome (ACS) and stroke. Activation of coagulation cascade is a key step of the thrombotic process: vessel injury results in exposure of the glycoprotein tissue factor (TF) to the flowing blood. Once exposed, TF binds factor VII/VIIa (FVII/FVIIa) and in presence of calcium ions, it forms a tertiary complex able to activate FX to FXa, FIX to FIXa, and FVIIa itself. The final step is thrombin formation at the site of vessel injury with subsequent platelet activation, fibrinogen to fibrin conversion and ultimately thrombus formation. Platelets are the key cells in primary hemostasis.
    [Show full text]
  • Proquest Dissertations
    urn u Ottawa L'Universitd canadienne Canada's university FACULTE DES ETUDES SUPERIEURES l^^l FACULTY OF GRADUATE AND ET POSTDOCTORALES u Ottawa POSTDOCTORAL STUDIES I.'University emiadienne Canada's university Charles Gyamera-Acheampong AUTEUR DE LA THESE / AUTHOR OF THESIS Ph.D. (Biochemistry) GRADE/DEGREE Biochemistry, Microbiology and Immunology FACULTE, ECOLE, DEPARTEMENT / FACULTY, SCHOOL, DEPARTMENT The Physiology and Biochemistry of the Fertility Enzyme Proprotein Convertase Subtilisin/Kexin Type 4 TITRE DE LA THESE / TITLE OF THESIS M. Mbikay TIRECTWRTDIRICTR^ CO-DIRECTEUR (CO-DIRECTRICE) DE LA THESE / THESIS CO-SUPERVISOR EXAMINATEURS (EXAMINATRICES) DE LA THESE/THESIS EXAMINERS A. Basak G. Cooke F .Kan V. Mezl Gary W. Slater Le Doyen de la Faculte des etudes superieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-59504-6 Our file Notre reference ISBN: 978-0-494-59504-6 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats.
    [Show full text]